Melissa Vrohlings

1.6k total citations · 1 hit paper
11 papers, 1.2k citations indexed

About

Melissa Vrohlings is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Melissa Vrohlings has authored 11 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 6 papers in Immunology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Melissa Vrohlings's work include CAR-T cell therapy research (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Immunotherapy and Immune Responses (3 papers). Melissa Vrohlings is often cited by papers focused on CAR-T cell therapy research (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Immunotherapy and Immune Responses (3 papers). Melissa Vrohlings collaborates with scholars based in Switzerland, United States and Japan. Melissa Vrohlings's co-authors include Burkhard Becher, Johannes vom Berg, Paulina Kulig, Sara Burkhard, Kathrin Nussbaum, Isabel Ohs, Sònia Tugues, Emmanuel L. Gautier, Ryuichi Nishinakamura and Anne Buttgereit and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Melissa Vrohlings

9 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sall1 is a transcriptional regulator defining microglia identity and function

2016 413 citations Anne Buttgereit, Iva Lelios et al. Nature Immunology profile →

Peers

Countries citing papers authored by Melissa Vrohlings

Since Specialization

Citations

This map shows the geographic impact of Melissa Vrohlings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Vrohlings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Vrohlings more than expected).

Fields of papers citing papers by Melissa Vrohlings

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Vrohlings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Vrohlings. The network helps show where Melissa Vrohlings may publish in the future.

Co-authorship network of co-authors of Melissa Vrohlings

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Vrohlings. A scholar is included among the top collaborators of Melissa Vrohlings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Vrohlings. Melissa Vrohlings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	In silico tumor immune microenvironment (TiME) analysis of non-small cell lung cancer (NSCLC) to inform clinical development of CDR404: A first-of-its-kind MAGE-A4 targeted T-cell engager. 2024 ·Journal of Clinical Oncology ·(unknown), Melissa Vrohlings, Maria Bouvy‐Liivrand, Reija Hieta, Heather M. Shaw, Gilberto Lopes, (unknown), Swethajit Biswas	0
2	195 Overcoming the dose-response prediction limitation from bench to clinic for T-cell engagers: using quantitative systems pharmacology (QSP) modelling in the development of CDR404 for solid tumors 2023 ·SHILAP Revista de lepidopterología ·Melissa Vrohlings, (unknown), (unknown), Fei Hua, Stephanie Jungmichel, (unknown), (unknown), (unknown), Swethajit Biswas	1
3	200P Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager 2023 ·Annals of Oncology ·Giorgia Giacomazzi, (unknown), Reija Hieta, Nicholas Dupuis, Dieter Rondas, (unknown), Melissa Vrohlings, (unknown), (unknown), Subhra K. Biswas, Rom S. Leidner, (unknown)	1
4	Abstract 2891: Enhanced anti-tumor responses with a novel dual pMHC T-cell engager bispecific antibody 2022 ·Cancer Research ·Stephanie Jungmichel, (unknown), (unknown), (unknown), (unknown), Philip A. Knobel, (unknown), Melissa Vrohlings, (unknown), (unknown), (unknown), Christian Leisner, (unknown)	2
5	An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus 2021 ·npj Vaccines ·Armando Zúñiga, (unknown), Melissa Vrohlings, (unknown), Kerstin Moehle, John A. Robinson, (unknown)	12
6	Author Correction: An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus 2021 ·npj Vaccines ·Armando Zúñiga, (unknown), Melissa Vrohlings, (unknown), Kerstin Moehle, John A. Robinson, (unknown)	0
7	Preclinical Assessment of CDR101 - a BCMAxCD3xPD-L1 Trispecific Antibody with Superior Anti-Tumor Efficacy 2021 ·Blood ·Melissa Vrohlings, Jan Müller, Stephanie Jungmichel, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Christian Leisner, Markus G. Manz, (unknown)	13
8	Sall1 is a transcriptional regulator defining microglia identity and function breakdown → 2016 ·Nature Immunology ·Anne Buttgereit, Iva Lelios, (unknown), Melissa Vrohlings, (unknown), Emmanuel L. Gautier, Ryuichi Nishinakamura, Burkhard Becher, Melanie Greter	413
9	New insights into IL-12-mediated tumor suppression 2014 ·Cell Death and Differentiation ·Sònia Tugues, Sara Burkhard, Isabel Ohs, Melissa Vrohlings, Kathrin Nussbaum, Johannes vom Berg, Paulina Kulig, Burkhard Becher	415
10	Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model 2013 ·The Journal of Immunology ·Alexandra Sevko, Tillmann Michels, Melissa Vrohlings, Ludmila Umansky, Philipp Beckhove, Masashi Kato, Galina V. Shurin, Michael R. Shurin, Viktor Umansky	195
11	Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection 2013 ·The Journal of Experimental Medicine ·Johannes vom Berg, Melissa Vrohlings, (unknown), A Haimovici, Paulina Kulig, Anna Śledzińska, Michael Weller, Burkhard Becher	157

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact